Profile
Kerry Russell worked as Vice President-Clinical Development at Dicerna Pharmaceuticals, Inc. from 2020 to 2022.
Dr. Russell also held the same position at resTORbio, Inc. Dr. Russell then became the Chief Medical Officer-Metabolic at Terns Pharmaceuticals, Inc. in 2023.
Dr. Russell completed an undergraduate degree at Rice University and obtained doctorate degrees from The University of Texas at Austin and The University of Texas Health Science Center at Houston.
Former positions of Kerry Russell
| Companies | Position | End |
|---|---|---|
| TERNS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 30/04/2023 |
| DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 30/04/2022 |
| DICERNA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| ADICET BIO, INC. | Corporate Officer/Principal | - |
Training of Kerry Russell
| Rice University | Undergraduate Degree |
| The University of Texas at Austin | Doctorate Degree |
| The University of Texas Health Science Center at Houston | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| TERNS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Kerry Russell